PHIL in the Treatment of Intracranial dAVF.
Completed · Not applicable · NCT03467542
Conditions: Arteriovenous Dural Fistula
At a glance
- Research payments reported, 2025
- $18,760
- U.S. investigators named
- 6
- Sites paid
- 6
- Planned or actual enrollment
- 64
About the trial
- Sponsor
- Microvention-Terumo, Inc.
- Tested
- PHIL® Liquid Embolic System (device)
- Dates
- Started 2018-08-24; completion 2022-12-12
- Results posted
- Yes
This study is a prospective, multicenter, single-arm study. Patients with Dural Arteriovenous Fistulas (dAVF) have a few choice for safe treatment. In this study, all patients with qualifying dAVFs will be treated with PHIL® Liquid Embolic material.
From ClinicalTrials.gov, last updated 2024-12-31. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Microvention, Inc. reported $18,760 in research payments for this study in 2025 (7 payments).
Products named: Stent, Phil
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Gary Duckwiler, MD Interventional Radiology · Los Angeles, CA
- Edgar A. Samaniego Ponton, M.D. Interventional Radiology · Iowa City, IA
- Michael Chen, M.D. Neurology · Chicago, IL
- Arindam R. Chatterjee, MD Neuroradiology · Saint Louis, MO
- Tomoyoshi Shigematsu, M.D., PH.D. Neurosurgery · New York, NY
- Violiza I. Acosta, M.D. Neurology · Memphis, TN
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Washington University $12,274
- Semmes Murphey Foundation $2,200
- Ronald Reagan UCLA Medical Center, CA $1,260
- Icahn School of Medicine $1,200
- Rush University Medical Center, IL $975
- University of Iowa Hospital & Clinics, IA $851
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.